Press Releases

08.17.2017

Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin)

08.03.2017

FDA Advisory Committee Votes in Favor of XELJANZ® (tofacitinib citrate) for the Treatment of Active Psoriatic Arthritis

08.01.2017

Pfizer Reports Second-Quarter 2017 Results

07.25.2017

CONSORTIUM ESTABLISHED TO SUPPORT ICH M7 COMPLIANCE

07.25.2017

Interest from startups in the BaseLaunch healthcare accelerator exceeds expectations

07.24.2017

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab)

07.21.2017

EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

07.20.2017

Merck and Pfizer Collaborate with Corning

07.19.2017

Pfizer Completes License Agreement For The Exclusive Commercialization Rights In Europe For CRESEMBA (isavuconazole)

07.13.2017

Pfizer Announces FDA Accepts Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

07.11.2017

FDA Advisory Committee Votes in Favor of Pfizer’s MYLOTARG (gemtuzumab ozogamicin) for Acute Myeloid Leukemia

07.10.2017

Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress